Aileron Therap’s (NASDAQ:ALRN) quiet period is set to end on Tuesday, August 8th. Aileron Therap had issued 3,750,000 shares in its initial public offering on June 29th. The total size of the offering was $56,250,000 based on an initial share price of $15.00. During Aileron Therap’s quiet period, insiders and underwriters involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

A number of equities analysts have issued reports on ALRN shares. Jefferies Group LLC started coverage on Aileron Therap in a research note on Monday, July 24th. They set a “buy” rating and a $20.00 price target for the company. William Blair started coverage on Aileron Therap in a research note on Monday, July 24th. They set an “outperform” rating for the company. Bank of America Corporation started coverage on Aileron Therap in a research note on Monday, July 24th. They set a “buy” rating and a $19.00 price target for the company. Finally, Canaccord Genuity started coverage on Aileron Therap in a research note on Monday, July 24th. They set a “buy” rating and a $19.00 price target for the company.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/08/07/aileron-theraps-nasdaqalrn-quiet-period-will-end-tomorrow.html.

Aileron Therap (NASDAQ ALRN) opened at 12.14 on Monday. The company’s market cap is $178.58 million. Aileron Therap has a 52-week low of $10.37 and a 52-week high of $14.32. The firm’s 50 day moving average is $12.92 and its 200 day moving average is $12.92.

In other news, insider Lilly Ventures Fund I. Llc purchased 250,000 shares of the business’s stock in a transaction dated Wednesday, July 5th. The shares were purchased at an average price of $15.00 per share, for a total transaction of $3,750,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Cvf, Llc purchased 180,000 shares of the business’s stock in a transaction dated Wednesday, July 5th. The shares were purchased at an average price of $15.00 per share, for a total transaction of $2,700,000.00. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 696,667 shares of company stock worth $10,450,005. Corporate insiders own 68.10% of the company’s stock.

An institutional investor recently bought a new position in Aileron Therap stock. Candriam Luxembourg S.C.A. purchased a new position in shares of Aileron Therap (NASDAQ:ALRN) during the second quarter, according to its most recent filing with the SEC. The fund purchased 150,000 shares of the company’s stock, valued at approximately $1,673,000. Candriam Luxembourg S.C.A. owned 1.02% of Aileron Therap at the end of the most recent quarter.

Aileron Therap Company Profile

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Receive News & Stock Ratings for Aileron Therap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therap and related stocks with our FREE daily email newsletter.